



An Anthem Company

## NEW YORK Provider Communications

### Medical Policies and Clinical Utilization Management Guidelines update

Published: Dec 1, 2018 - **State & Federal** / Medicaid

The *Medical Policies* and *Clinical Utilization Management (UM) Guidelines* below were developed or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed. For markets with carved-out pharmacy services, the applicable listings below are informational only.

#### Note:

- Effective November 1, 2018, AIM Specialty Health's (AIM) *Musculoskeletal Level of Care Guidelines*, *Sleep Study Guidelines* and *Advanced Imaging Guidelines* will be used for clinical reviews.
- When requesting services for a patient (including medical procedures and medications), the Precertification Look-Up Tool may indicate that precertification is not required, but this does not guarantee payment for services rendered; a *Medical Policy* or *Clinical UM Guideline* may deem the service investigational or not medically necessary. In order to determine if services will qualify for payment, please ensure applicable clinical criteria is reviewed prior to rendering services.

Please share this notice with other members of your practice and office staff.

To search for specific policies or guidelines, visit  
<http://www.empireblue.com/medicalpolicies/search.html>.

#### **Medical Policies**

On July 26, 2018, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following *Medical Policies* applicable to Empire BlueCross BlueShield HealthPlus (Empire).

| <b>Publish date</b> | <b>Medical Policy number</b> | <b>Medical Policy title</b>   |
|---------------------|------------------------------|---|
| 8/29/2018           | DRUG.00096                   | Ibalizumab-uiyk (Trogarzo™)   |
| 8/29/2018           | GENE.00049                   | Circulating Tumor DNA Testing for Cancer (Liquid Biopsy)                                      |
| 8/29/2018           | ADMIN.00007                  | Immunizations   |
| 8/29/2018           | DRUG.00046                   | Ipilimumab (Yervoy®)  |
| 8/29/2018           | DRUG.00050                   | Eculizumab (Soliris®)   |
| 8/2/2018            | DRUG.00067                   | Ramucirumab (Cyramza®)  |
| 8/2/2018            | DRUG.00071                   | Pembrolizumab (Keytruda®)   |
| 8/29/2018           | DRUG.00075                   | Nivolumab (Opdivo®)   |
| 8/29/2018           | DRUG.00088                   | Atezolizumab (Tecentriq®)   |
| 8/29/2018           | DRUG.00098                   | Lutetium Lu 177 dotatate (Lutathera®)   |
| 8/29/2018           | GENE.00006                   | Epidermal Growth Factor Receptor (EGFR) Testing   |
| 8/2/2018            | GENE.00011                   | Gene Expression Profiling for Managing Breast Cancer Treatment                                |
| 8/29/2018           | GENE.00025                   | Molecular Profiling and Proteogenomic Testing for the Evaluation of Malignant Tumors          |
| 8/29/2018           | GENE.00029                   | Genetic Testing for Breast and/or Ovarian Cancer Syndrome                                     |
| 8/2/2018            | MED.00124                    | Tisagenlecleucel (Kymriah®)   |
| 8/2/2018            | SURG.00023                   | Breast Procedures including Reconstructive Surgery, Implants and Other Breast Procedures      |
| 8/2/2018            | SURG.00032                   | Transcatheter Closure of Patent Foramen Ovale and Left Atrial Appendage for Stroke Prevention |

### **Clinical UM Guidelines**

On July 26, 2018, the MPTAC approved the following *Clinical UM Guidelines* applicable to Empire. This list represents the guidelines adopted by the medical operations committee for the Government Business Division on August 31, 2018.

| <b>Publish date</b> | <b>Clinical UM Guideline number</b> | <b>Clinical UM Guideline title</b> | <b>New or Revised</b> |
|---------------------|-------------------------------------|------------------------------------|-----------------------|
| 9/20/2018           | CG-DME-45                           | Ultrasound Bone Growth Stimulation | New                   |
| 9/20/2018           | CG-DRUG-103                         | Botulinum Toxin                    | New                   |
| 9/20/2018           | CG-DRUG-104                         | Omalizumab (Xolair®)               | New                   |
| 9/20/2018           | CG-DRUG-105                         | Abatacept (Orencia®)               | New                   |
| 9/20/2018           | CG-DRUG-106                         | Brentuximab Vedotin (Adcetris®)    | New                   |

|            |             |   |         |
|------------|-------------|---|---------|
| 9/20/2018  | CG-DRUG-107 | Pharmacotherapy for Hereditary Angioedema   | New     |
| 9/20/2018  | CG-DRUG-108 | Enteral Carbidopa and Levodopa Intestinal Gel Suspension  | New     |
| 9/20/2018  | CG-DRUG-109 | Asfotase Alfa (Strensiq™)   | New     |
| 9/20/2018  | CG-DRUG-110 | Naltrexone Implantable Pellets  | New     |
| 9/20/2018  | CG-DRUG-111 | Sebelipase alfa (KANUMA™)   | New     |
| 9/20/2018  | CG-DRUG-112 | Abaloparatide (Tymlos™) Injection   | New     |
| 9/20/2018  | CG-MED-73   | Hyperbaric Oxygen Therapy (Systemic/Topical)  | New     |
| 9/20/2018  | CG-MED-74   | Implantable Ambulatory Event Monitors and Mobile Cardiac Telemetry  | New     |
| 9/20/2018  | CG-MED-75   | Medical and Other Non-Behavioral Health-Related Treatments for Autism Spectrum Disorders and Rett Syndrome  | New     |
| 9/20/2018  | CG-MED-76   | Magnetic Source Imaging and Magnetoencephalography  | New     |
| 9/20/2018  | CG-MED-77   | SPECT/CT Fusion Imaging   | New     |
| 9/20/2018  | CG-REHAB-11 | Cognitive Rehabilitation  | New     |
| 9/20/2018  | CG-SURG-81  | Cochlear Implants and Auditory Brainstem Implants   | New     |
| 9/20/2018  | CG-SURG-82  | Bone-Anchored and Bone Conduction Hearing Aids  | New     |
| 10/31/2018 | CG-SURG-83  | Bariatric Surgery and Other Treatments for Clinically Severe Obesity  | New     |
| 9/20/2018  | CG-SURG-84  | Mandibular/Maxillary (Orthognathic) Surgery   | New     |
| 10/31/2018 | CG-SURG-85  | Hip Resurfacing   | New     |
| 10/31/2018 | CG-SURG-86  | Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection   | New     |
| 9/20/2018  | CG-SURG-87  | Nasal Surgery for the Treatment of Obstructive Sleep Apnea and Snoring Previous title: Nasal Surgery for the Treatment of Obstructive Sleep Apnea and Snoring | New     |
| 9/20/2018  | CG-SURG-88  | Mastectomy for Gynecomastia   | New     |
| 9/20/2018  | CG-SURG-89  | Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia  | New     |
| 8/29/2018  | CG-ADMIN-02 | Clinically Equivalent Cost Effective Services — Targeted Immune Modulators  | Revised |
| 8/29/2018  | CG-DRUG-09  | Immune Globulin (Ig) Therapy  | Revised |
| 8/29/2018  | CG-DRUG-65  | Tumor Necrosis Factor Antagonists   | Revised |

|           |            |   |         |
|-----------|------------|---|---------|
| 8/29/2018 | CG-DRUG-68 | Bevacizumab (Avastin®) for Non-Ophthalmologic Indications   | Revised |
| 8/29/2018 | CG-DRUG-73 | Denosumab (Prolia®, Xgeva®)   | Revised |
| 8/29/2018 | CG-DRUG-81 | Tocilizumab (Actemra®)  | Revised |
| 8/29/2018 | CG-GENE-03 | BRAF Mutation Analysis  | Revised |
| 8/29/2018 | CG-MED-35  | Retinal Telescreening Systems   | Revised |
| 8/29/2018 | CG-MED-71  | Wound Care in the Home Setting  | Revised |
| 8/2/2018  | CG-SURG-24 | Functional Endoscopic Sinus Surgery (FESS)  | Revised |
| 8/29/2018 | CG-SURG-49 | Endovascular Techniques (Percutaneous or Open Exposure) for Arterial Revascularization of the Lower Extremities | Revised |
| 8/2/2018  | CG-SURG-73 | Balloon Sinus Ostial Dilatation   | Revised |

**URL:** <https://providernews.empireblue.com/article/medical-policies-and-clinical-utilization-management-guidelines-update-6>

**Featured In:**

December 2018 Empire Provider Newsletter

Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc. licensees of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans, serving residents and businesses in the 28 eastern and southeastern counties of New York State. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. All external sites will open in a new browser window. Please view our Website Privacy Policy for more information.

---